Abstract
The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide’s role in acute and chronic inflammation.
Keywords: Anti-inflammatory, Curcuma longa, NR-INF-02, Polysaccharide fraction.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02)
Volume: 14 Issue: 1
Author(s): Ramanaiah Illuri, Bharathi Bethapudi, Senthilkumar Anandakumar, Sasikumar Murugan, Joshua A. Joseph, Deepak Mundkinajeddu, Amit Agarwal and Chandrasekaran C.V.
Affiliation:
Keywords: Anti-inflammatory, Curcuma longa, NR-INF-02, Polysaccharide fraction.
Abstract: The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide’s role in acute and chronic inflammation.
Export Options
About this article
Cite this article as:
Illuri Ramanaiah, Bethapudi Bharathi, Anandakumar Senthilkumar, Murugan Sasikumar, Joseph A. Joshua, Mundkinajeddu Deepak, Agarwal Amit and C.V. Chandrasekaran, Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02), Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14 (1) . https://dx.doi.org/10.2174/1871523014666150407150533
DOI https://dx.doi.org/10.2174/1871523014666150407150533 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Behcets Syndrome: Literature Review
Current Rheumatology Reviews Sterol Biosynthesis Pathway as an Alternative for the Anti-Protozoan Parasite Chemotherapy
Current Medicinal Chemistry Ascorbic Acid and Gene Expression: Another Example of Regulation of Gene Expression by Small Molecules?
Current Genomics Chemical and Medicinal Versatility of Substituted 1,4-Dihydropyridines
Current Bioactive Compounds Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Nanomedicine: Potential Devices for Diagnostics
Recent Patents on Nanomedicine A Comprehensive Review of the Genus Pyrola Herbs in Traditional Uses, Phytochemistry and Pharmacological Activities
Current Topics in Medicinal Chemistry The Manzamines as an Example of the Unique Structural Classes Available for the Discovery and Optimization of Infectious Disease Controls Based on Marine Natural Products
Current Pharmaceutical Design Screening Strategies to Identify New Antibiotics
Current Drug Targets Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia
Current Topics in Medicinal Chemistry Recent Patents on Oral Combination Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
Current Pharmaceutical Design Leptin and Inflammation
Current Immunology Reviews (Discontinued) Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers
Current Drug Delivery Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Update on Anti-TNF-Alpha Treatment in Rheumatic Diseases
Current Drug Therapy Bacterial Proteases in Disease – Role in Intracellular Survival, Evasion of Coagulation/ Fibrinolysis Innate Defenses, Toxicoses and Viral Infections
Current Pharmaceutical Design